Shares of Cadila Healthcare slipped more than 10% intraday on Thursday on reports that the US Food and Drug Administration (FDA) has raised concerns over the manufacturing process of at least one product at Cadila’s Moraiya facility.
As per the Reuters report, the US FDA had not raised concerns over the entire facility.
The Cadila Healthcare Ltd scrip was trading 4.54% lower at Rs 1112.55 on the BSE at 1.40 pm IST.
Also Read
World’s fastest bowler: Morne Morkel at a humongous 173.9 kmph at IPL 2013, but Hawk-Eye was not looking
Shraddha Kapoor on money, sex and Rs 100 crore club
Sunny Leone to be romanced by Ram Kapoor in ‘Patel Rap’
Chef turned woman into ?200-a-night prostitute
